Weave Comm.

Weave did $239 million in 2025 revenue, but one published 2026 estimate says $2.0 billion. Same company. Same calendar.

If you own WEAV, you need to watch whether growth finally turns into actual profit.

weav

technology · software small cap updated mar 13, 2026
$5.33
market cap ~$384M · 52-week range $5–$12
xvary composite: 47 / 100 · below average
our overall rating — combines growth, value, risk, and momentum
Start here if you're new
what it is
Weave sells software that helps small businesses call, text, schedule, and get paid without playing phone tag all day.
how it gets paid
Last year Weave Comm made $239M in revenue. core communications platform was the main engine at $119.5M, or 50% of sales.
why it's growing
Revenue grew 17.0% last year. 71.9% gross margin matters most because it shows the product is attractive before sales and overhead eat the economics.
what just happened
Weave put up $176M in the latest quarter, but the cleaner read is still the full-year business at $239M of revenue and a -$0.44 trailing EPS.
At a glance
B balance sheet — gets the job done, barely
-$0.36 fy2025 eps est
$2B fy2026 rev est
12.8% operating margin
1.75 beta
xvary composite: 47/100 — below average
What they do
Weave sells software that helps small businesses call, text, schedule, and get paid without playing phone tag all day.
Weave wins by bundling phone, text, payments, and staff messaging into one workflow for small offices. That means your front desk does less app-switching and fewer missed calls turn into lost customers. The proof is simple: gross margin hit 71.9% in 2025, which means the software is cheap to deliver once customers are in.
software small-cap saas healthcare-smb ai-tools
How they make money
$239M annual revenue · their business grew +17.0% last year
core communications platform
$119.5M
texting and missed-call tools
$47.8M
payments and engagement
$35.9M
phone system and call handling
$23.9M
mobile app and team messaging
$11.9M
The products that matter
subscription software platform
Subscription & Services
$226M · 94.6% of revenue
this is the business. it produced $226M of revenue, or 94.6% of total sales, and it sits behind the 73.3% gross margin that makes the story investable at all.
94.6% of revenue
hardware and other add-ons
Hardware & Other
$13M · 5.4% of revenue
it's only $13M, or 5.4% of revenue. useful for workflow and onboarding, but not the reason you own the stock.
small contributor
patient financing integration
CareCredit Integration
supports 2026 plan
management is using new payments and financing features to support the $273M–$276M 2026 revenue plan. On this snapshot, the revenue contribution is still thesis, not evidence.
unproven catalyst
Key numbers
$239M
2025 revenue
That is the real size of the business today. Everything else is just projection.
71.9%
gross margin
Gross margin → money left after delivering the product → so what: the software model works before overhead shows up.
12.8%
operating margin
Operating margin → profit after running the business → so what: Weave still loses money even after decent scale.
$42M
long-term debt
Debt is only about 10% of capital, so the balance sheet is not the main problem. Execution is.
Financial health
B
strength
  • balance sheet grade B — adequate — nothing special
  • risk rank 3 — safer than 50% of stocks
  • price stability 5 / 100
  • long-term debt $42M (10% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market

Return history isn't available for WEAV right now.

source: institutional data · return history unavailable
What just happened
beat estimates
Weave put up $176M in the latest quarter, but the cleaner read is still the full-year business at $239M of revenue and a -$0.44 trailing EPS.
Gross margin reached 71.9%, which says the software economics are solid. The problem is below that line, where operating margin stayed negative at -12.8%.
$176M
revenue
$0.35
eps
71.9%
gross margin
the number that mattered
71.9% gross margin matters most because it shows the product is attractive before sales and overhead eat the economics.
source: company earnings report, 2026

Get this snapshot in your inbox

This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.

weekly updates earnings alerts plain english no spam
What could go wrong

the #1 risk is decelerating growth before durable profitability arrives.

med
Revenue growth is already stepping down
Management's $273M–$276M 2026 target implies roughly 14.8% growth, down from 17.0% last year. That's not a collapse. It is enough to keep the valuation from expanding if investors wanted acceleration.
At about 1.4x forward sales, the stock looks cheap for software. If growth keeps fading while EPS stays negative, cheap does not protect you.
med
Retention is stable, not bulletproof
Management points to retention stabilizing in the 91%–93% range. That's good enough to support the model. It is not the kind of number that lets you stop monitoring churn.
If retention breaks below that band, the stickiness argument weakens fast because the bull case leans on recurring revenue inside a narrow healthcare niche.
med
One profitable quarter is not full-year profitability
Q3 2025 EPS was $0.02. The full-year estimate is still -$0.36. That gap is the story: the model is improving, but it has not crossed the line on a sustained basis.
If margin gains stop or operating costs stay heavy, investors keep treating every profitable quarter as a nice surprise instead of a new baseline.
med
An 84% institutional cap table can amplify the swings
About 84% institutional ownership is a lot for a ~$384M company. In plain English: a small number of professional holders can move this stock harder than the fundamentals alone would suggest.
That concentration creates support on the way up and air pockets on the way down. The 5 / 100 price stability score says you've already met the second version.
These risks all hit the same nerve: a company with strong software gross margins still needs growth, retention, and real profitability to line up at the same time.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next earnings report
Estimated for Monday, May 4, 2026. Consensus EPS is $0.03. Another small profit would help. A miss would put the full-year loss story back in charge.
trend
whether 14.8% growth is the floor or the new pace
The current 2026 target points to a slower year than 2025's 17.0% growth. If you own the stock, this is the cleanest test of whether the sell-off went too far or not far enough.
metric
retention inside the 91%–93% band
Retention is the simplest reality check on product stickiness here. Stable is good. A break below the current band would make the moat argument look thin fast.
risk
what management proves on AI and payments
New feature language is not the result. The result is faster growth, better retention, or higher margin. Until one of those numbers moves, the story stays in prove-it mode.
Analyst rankings
risk profile
average
risk rank 3 — typical risk profile — neither especially safe nor risky.
chart momentum
below average
momentum rank 4 — analysts see underperformance risk in the near term.
source: institutional data
Institutional activity

institutional ownership data for WEAV is being compiled.

source: institutional data
Price targets
3-5 year target range
n/a n/a
$5 current price
n/a target midpoint · n/a from current
target data not available

Want the deeper analysis?

The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.

see plans from $5/mo
The deep dive
WEAV
xvary deep dive
weav
the full analysis is in the works.
what you'll get
dcf valuation model
bull / base / bear scenarios
competitive moat breakdown
quarterly earnings tracker
operating model projections
risk matrix with kill criteria
original price target + conviction
updated with every earnings
free · no spam · you'll be first to read it